Transpek Industry Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹629 Cr
Transpek Industry Limited expects a revenue growth of 15% to 20% for the current financial year (FY27) compared to the previous year. Transpek expects revenue growth of 15% to 20% in the current year (FY27), driven by volume and value increases.
From Transpek Industry Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Price
₹1,380
Market Cap
₹629 Cr
P/E Ratio
16.1
Revenue Rank
Margin Rank
How does Transpek Industry Ltd rank in Chemicals & Petrochemicals?
Compare Transpek Industry Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Transpek Industry Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹148 Cr, net profit ₹7 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →Transpek Industry Limited expects a revenue growth of 15% to 20% for the current financial year (FY27) compared to the previous year.
- →Growth is driven by volume plus value increase, with some products like acid chlorides already showing higher revenue (INR4 crores last year to an expected INR15 crores this year).
- →The company plans to double its size and business in the next 5 years based on finalized strategies focusing on core product profiles and applications.
- →New product commercialization is anticipated with two products expected to bring around INR50 crores each annually once fully commercialized.
- →Some capex is planned ahead of confirmed demand based on market studies and customer relationships to support growth.
- →Long-term contracts and customer discussions (e.g., with Arclin) provide reasonable visibility, though short-term contracts can be volatile.
- →Overall, the company is cautiously optimistic given industry volatility but aims for steady and meaningful growth.
📈 Profitability & Margins
Rank 3- →Transpek expects revenue growth of 15% to 20% in the current year (FY27), driven by volume and value increases.
- →EBITDA margin is targeted in the range of 15% to 20%, maintaining consistency seen over the past 8-10 years.
- →Some products may yield higher margins, others lower, but overall margin guidance remains steady.
- →The company aims to double its business size over the next 5 years, focusing on core product areas and new product launches.
- →New product commercialization is expected to contribute incremental revenue of approximately INR50 crores per product annually (two such products near commercialization).
- →Capex is being planned both on confirmed customer demand and market opportunities, including a new multi-purpose pilot plant.
- →Payback for the INR250 crores Odisha plant investment is expected within 4 to 5 years.
- →Market volatility, especially raw material price swings, may impact margins in the short term, but Transpek plans to sustain market share.
🏗️ Capital Expenditure Plans
Yes- →Planned capex of around INR 250 crores over 5-6 years, phased.
- →Odisha greenfield project: Board approval sought within 25-30 days; feasibility study filing and government presentations expected by Sept-Nov 2026.
- →Project timelines: 3-4 months for permissions post-approval, with 1-2 years for construction and commercial production.
- →Multi-purpose pilot plant at Ekalbara (not Odisha) to scale-up products from kilo-lab to tonnage, expected operational by Feb 2027.
- →Continued investment in new product development; aiming for commercialization of several products generating INR 50-100 crores annually.
- →Past capex (~INR 200 crores last 5-6 years) largely maintenance and captive consumption expansions, not growth-focused.
- →Strategy to invest ahead of confirmed demand for select products based on market studies and customer visibility.
- →No current product discontinuation; capacity utilization constrained by permits and product-specific streams.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
No information- →The transcript does not explicitly mention the current or expected order book or pending orders in specific figures.
- →Bimal Mehta highlights that some customers are currently working with Transpek, providing clear visibility of demand for certain products.
- →Discussions with customers for new contracts, including sizeable contracts similar to DuPont, are ongoing but delayed due to market volatility and cautious decision-making.
- →Transpek has shifted from a very conservative capex approach to investing ahead of confirmed demand based on market studies and customer relationships.
- →New products are under development, with expected revenue streams emerging by the end of the current financial year and the next year.
- →No specific quantitative data on current order book or pending orders was disclosed during the call.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Transpek Industry Ltd Q1 FY27 results?
Transpek Industry Limited expects a revenue growth of 15% to 20% for the current financial year (FY27) compared to the previous year. Transpek expects revenue growth of 15% to 20% in the current year (FY27), driven by volume and value increases.
What is Transpek Industry Ltd share price analysis?
Transpek Industry Ltd currently shows a below-average growth signal. The stock trades at a P/E of 16.1 with a market cap of ₹629 Cr. Investors should review the full earnings analysis for detailed insights.
Is Transpek Industry Ltd planning capital expenditure?
Planned capex of around INR 250 crores over 5-6 years, phased.
Keep Transpek Industry Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.